Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
-
Sanofi Video Q&A: CFO Jérôme Contamine Comments on Q3 2011 Results
-
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
-
Regeneron Reports Third Quarter 2011 Financial and Operating Results
-
Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
